BACKGROUND: Platelet dysfunction is known to occur in patients with traumatic brain injury (TBI), and the correction of platelet dysfunction may prevent hemorrhagic progression in TBI. Thromboelastography with platelet mapping (TEG-PM; Haemonetics) evaluates the degree of platelet function inhibition through the adenosine diphosphate (ADP) and arachidonic acid (AA) pathways. We hypothesized that ADP and AA inhibition would improve with the transfusion of platelets in patients with TBI. METHODS: A retrospective review was conducted at a Level I trauma center of all patients presenting with TBI from December 2019 to December 2020. Per a practice management guideline, a platelet mapping assay was obtained on all patients with TBI upon admission. If ADP or AA was found to be inhibited (>60%), the patient was transfused 1 unit of platelets and a repeat platelet mapping assay was ordered. Demographic data, laboratory values, and outcomes were analyzed. RESULTS: Over the 13-month study period, 453 patients with TBI underwent TEG-PM with a protocol adherence rate of 66.5% resulting in a total of 147 patients who received platelets for ADP and/or AA inhibition; of those, 107 underwent repeat TEG-PM after platelets were administered. With the administration of platelets, ADP (p < 0.0001), AA (p < 0.0001), and MA (p = 0.0002) all significantly improved. Of 330 patients with TBI not taking antiplatelet medications, 50.9% showed inhibition in ADP and/or AA. If AA or ADP inhibition was noted on admission, mortality was increased (p = 0.0108). If ADP improved with platelet administration, the need for neurosurgical intervention was noted to decrease (p = 0.0182). CONCLUSION: Patients with TBI and platelet inhibition may benefit from the administration of platelets to correct platelet dysfunction. Thromboelastography with platelet mapping may be implemented in the initial workup of patients presenting with TBI to assess platelet dysfunction and provide prognostic information, which may guide treatment. LEVEL OF EVIDENCE: Therapeutic / Care Management, level III.
Background: Patients with metabolic dysfunction–associated steatohepatitis (MASH) with advanced fibrosis are at risk for progression to cirrhosis and clinical outcomes, but can also experience fibrosis regression. The aim of this study was to compare risk stratification by the Enhanced Liver Fibrosis (ELF) Test to histological staging to assess patients at risk of disease progression and those likely to experience histological regression. Methods: Using pooled data from 6 large placebo-controlled trials of 2710 patients with advanced fibrosis due to MASH, 4 analyses of ELF and fibrosis stage were performed to evaluate the association with the following events: (1) liver-related clinical outcomes; (2) progression from bridging fibrosis to cirrhosis; (3) regression from bridging fibrosis; (4) regression from cirrhosis. Significance was assessed by interval likelihood ratio (iLR), Cox proportional hazard ratio (HR), and area under the receiver operator characteristic curve (AUROC). Results: In 2304 participants (17.8 mo mean follow-up), there was a progressive rise in liver-related outcome risk with increasing baseline ELF score [<9.00 (0%), ≥9.00 to <9.80 (2%), ≥9.80 to <11.30 (4%), ≥11.30 to <12.80 (13%), ≥12.80 (40%)]. In 1414 patients with bridging fibrosis, increasing baseline ELF scores were associated with a higher risk of progression to cirrhosis [<9.80 (9%), ≥9.80 to <11.30 (18%), ≥11.30 (45%)] and a lower likelihood of histological regression. In 1690 patients with cirrhosis, increasing baseline ELF scores were associated with a lower likelihood of histological regression [<9.80 (33%), ≥9.80 to <11.30 (16%), ≥11.30 (6%)]. In all analyses, the ELF Test provided more detailed information than histology. Conclusions: The ELF Test adds risk strata that are significantly different from fibrosis staging for the prediction of clinical events and histological changes, thereby improving risk stratification.
Background: Serum anti-Müllerian hormone (AMH) levels and antral follicle count are key in evaluating ovarian reserve (OR) for fertility. The performance of the Siemens Healthineers AMH assay was assessed on the ADVIA Centaur® System. Methods: Analytical characteristics, clinical performance, and method comparison studies were performed in a prospective cohort of 532 women at fertility clinics. Serum AMH levels were determined using ADVIA Centaur, Beckman Access®, and Roche Elecsys® assays. Results: The limit of quantitation for the ADVIA Centaur AMH assay was 0.030 ng/mL. Repeatability was ≤2.9% CV, within-lab repeatability was ≤3.2% CV, and reproducibility was ≤4.4% CV. Results using serum or lithium heparin sample types were equivalent. Diagnostic sensitivity across assays ranged from 77.3% to 90.2% and specificity ranged from 51.0 to 71.0%; corresponding positive and negative predictive values ranged from 66.6% to 74.3% and 74.2% to 83.0%, respectively. Receiver operating characteristic analyses demonstrated that the assays have a high probability for discriminating between diminished–normal and high OR. ADVIA and Beckman assays agreed according to ADVIA = 1.00 × Beckman + 0.014 ng/mL, τ = 0.909, while a more modest correlation of ADVIA = 1.41 × Roche − 0.024 ng/mL, τ = 0.777 was observed with Roche assay. Conclusions: The ADVIA Centaur assay demonstrates acceptable analytical characteristics and clinical performance comparable to the Roche AMH assay and is essentially interchangeable with the Beckman AMH assay for reliable OR assessment.